Zobrazeno 1 - 10
of 156
pro vyhledávání: '"R K, Oldham"'
This chapter presents results on the expansion and characterization of lymphocyte populations from human tumors. The lymphocytes that grew out of the tumor cell cultures were primarily T cells and were termed tumor-derived activated cells (TDAC). A p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1c094f910c2660d3139565231364620
https://doi.org/10.1201/9781003210115-10
https://doi.org/10.1201/9781003210115-10
Autor:
R K, Oldham
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 12:137-140
Autor:
R K, Oldham
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 14:413-415
Publikováno v:
Cancer biotherapyradiopharmaceuticals. 13(4)
The use of monoclonal antibodies (MoAbs) for immunotherapy and radioimmunotherapy has ushered in a new era in the treatment of non-Hodgkin's lymphoma.
Publikováno v:
In vivo (Athens, Greece). 8(5)
Interleukin-2 (Il-2) allows for the therapeutic augmentation of immunity in vivo and/or in vitro. In extensive studies in nearly 1000 patients with advanced cancer, we have demonstrated that Il-2 by continuous infusion, with cellular therapy (LAK or
Autor:
R K, Oldham
Publikováno v:
Immunology series. 61
Publikováno v:
Cancer. 71(7)
Interleukin-2 (IL-2), used alone or in combination with adoptive cellular therapy, is one of the most promising biologic therapeutic agents for cancer treatment.The National Biotherapy Study Group conducted 15 trials of continuous-infusion IL-2 invol
Autor:
R K, Oldham
Publikováno v:
Molecular biotherapy. 4(4)
Autor:
R K, Oldham
Publikováno v:
Molecular biotherapy. 4(1)
Publikováno v:
Molecular biotherapy. 4(1)
The National Biotherapy Study Group (NBSG) conducted a broad phase II trial using interleukin-2 (IL-2) by continuous infusion and alpha interferon (IFN) subcutaneously in 267 patients with a variety of advanced cancers, including 29 with breast cance